Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1991 Oct;64(4):624–630. doi: 10.1038/bjc.1991.374

Systemic immunotoxin therapy of cancer: advances and prospects.

E J Wawrzynczak 1
PMCID: PMC1977692  PMID: 1911210

Full text

PDF
628

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bagshawe K. D. The First Bagshawe lecture. Towards generating cytotoxic agents at cancer sites. Br J Cancer. 1989 Sep;60(3):275–281. doi: 10.1038/bjc.1989.270. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Blakey D. C., Skilleter D. N., Price R. J., Watson G. J., Hart L. I., Newell D. R., Thorpe P. E. Comparison of the pharmacokinetics and hepatotoxic effects of saporin and ricin A-chain immunotoxins on murine liver parenchymal cells. Cancer Res. 1988 Dec 15;48(24 Pt 1):7072–7078. [PubMed] [Google Scholar]
  3. Blättler W. A., Lambert J. M., Goldmacher V. S. Realizing the full potential of immunotoxins. Cancer Cells. 1989 Oct;1(2):50–55. [PubMed] [Google Scholar]
  4. Byers V. S., Rodvien R., Grant K., Durrant L. G., Hudson K. H., Baldwin R. W., Scannon P. J. Phase I study of monoclonal antibody-ricin A chain immunotoxin XomaZyme-791 in patients with metastatic colon cancer. Cancer Res. 1989 Nov 1;49(21):6153–6160. [PubMed] [Google Scholar]
  5. Chaudhary V. K., Gallo M. G., FitzGerald D. J., Pastan I. A recombinant single-chain immunotoxin composed of anti-Tac variable regions and a truncated diphtheria toxin. Proc Natl Acad Sci U S A. 1990 Dec;87(23):9491–9494. doi: 10.1073/pnas.87.23.9491. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Chaudhary V. K., Jinno Y., FitzGerald D., Pastan I. Pseudomonas exotoxin contains a specific sequence at the carboxyl terminus that is required for cytotoxicity. Proc Natl Acad Sci U S A. 1990 Jan;87(1):308–312. doi: 10.1073/pnas.87.1.308. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Chaudhary V. K., Queen C., Junghans R. P., Waldmann T. A., FitzGerald D. J., Pastan I. A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature. 1989 Jun 1;339(6223):394–397. doi: 10.1038/339394a0. [DOI] [PubMed] [Google Scholar]
  8. Colombatti M., Dell'Arciprete L., Chignola R., Tridente G. Carrier protein-monensin conjugates: enhancement of immunotoxin cytotoxicity and potential in tumor treatment. Cancer Res. 1990 Mar 1;50(5):1385–1391. [PubMed] [Google Scholar]
  9. Conde F. P., Orlandi R., Canevari S., Mezzanzanica D., Ripamonti M., Muñoz S. M., Jorge P., Colnaghi M. I. The Aspergillus toxin restriction is a suitable cytotoxic agent for generation of immunoconjugates with monoclonal antibodies directed against human carcinoma cells. Eur J Biochem. 1989 Jan 2;178(3):795–802. doi: 10.1111/j.1432-1033.1989.tb14511.x. [DOI] [PubMed] [Google Scholar]
  10. Durrant L. G., Byers V. S., Scannon P. J., Rodvien R., Grant K., Robins R. A., Marksman R. A., Baldwin R. W. Humoral immune responses to XMMCO-791-RTA immunotoxin in colorectal cancer patients. Clin Exp Immunol. 1989 Feb;75(2):258–264. [PMC free article] [PubMed] [Google Scholar]
  11. Embleton M. J. Drug-targeting by monoclonal antibodies. Br J Cancer. 1987 Mar;55(3):227–231. doi: 10.1038/bjc.1987.44. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Engert A., Martin G., Pfreundschuh M., Amlot P., Hsu S. M., Diehl V., Thorpe P. Antitumor effects of ricin A chain immunotoxins prepared from intact antibodies and Fab' fragments on solid human Hodgkin's disease tumors in mice. Cancer Res. 1990 May 15;50(10):2929–2935. [PubMed] [Google Scholar]
  13. Epenetos A. A., Kosmas C. Monoclonal antibodies for imaging and therapy. Br J Cancer. 1989 Feb;59(2):152–155. doi: 10.1038/bjc.1989.32. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. FitzGerald D., Pastan I. Targeted toxin therapy for the treatment of cancer. J Natl Cancer Inst. 1989 Oct 4;81(19):1455–1463. doi: 10.1093/jnci/81.19.1455. [DOI] [PubMed] [Google Scholar]
  15. Fulton R. J., Tucker T. F., Vitetta E. S., Uhr J. W. Pharmacokinetics of tumor-reactive immunotoxins in tumor-bearing mice: effect of antibody valency and deglycosylation of the ricin A chain on clearance and tumor localization. Cancer Res. 1988 May 1;48(9):2618–2625. [PubMed] [Google Scholar]
  16. Fulton R. J., Uhr J. W., Vitetta E. S. In vivo therapy of the BCL1 tumor: effect of immunotoxin valency and deglycosylation of the ricin A chain. Cancer Res. 1988 May 1;48(9):2626–2631. [PubMed] [Google Scholar]
  17. Ghetie M. A., May R. D., Till M., Uhr J. W., Ghetie V., Knowles P. P., Relf M., Brown A., Wallace P. M., Janossy G. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy. Cancer Res. 1988 May 1;48(9):2610–2617. [PubMed] [Google Scholar]
  18. Ghetie M. A., Uhr J. W., Vitetta E. S. Covalent binding of human alpha 2-macroglobulin to deglycosylated ricin A chain and its immunotoxins. Cancer Res. 1991 Mar 1;51(5):1482–1487. [PubMed] [Google Scholar]
  19. Gould B. J., Borowitz M. J., Groves E. S., Carter P. W., Anthony D., Weiner L. M., Frankel A. E. Phase I study of an anti-breast cancer immunotoxin by continuous infusion: report of a targeted toxic effect not predicted by animal studies. J Natl Cancer Inst. 1989 May 10;81(10):775–781. doi: 10.1093/jnci/81.10.775. [DOI] [PubMed] [Google Scholar]
  20. Hertler A. A., Frankel A. E. Immunotoxins: a clinical review of their use in the treatment of malignancies. J Clin Oncol. 1989 Dec;7(12):1932–1942. doi: 10.1200/JCO.1989.7.12.1932. [DOI] [PubMed] [Google Scholar]
  21. Hertler A. A., Schlossman D. M., Borowitz M. J., Blythman H. E., Casellas P., Frankel A. E. An anti-CD5 immunotoxin for chronic lymphocytic leukemia: enhancement of cytotoxicity with human serum albumin-monensin. Int J Cancer. 1989 Feb 15;43(2):215–219. doi: 10.1002/ijc.2910430207. [DOI] [PubMed] [Google Scholar]
  22. Hertler A. A., Schlossman D. M., Borowitz M. J., Poplack D. G., Frankel A. E. An immunotoxin for the treatment of T-acute lymphoblastic leukemic meningitis: studies in rhesus monkeys. Cancer Immunol Immunother. 1989;28(1):59–66. doi: 10.1007/BF00205802. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Ito T., Qiu H., Collins J. A., Brill A. B., Johnson D. K., Griffin T. W. Preclinical assessments of 90Y-labeled C110 anti-carcinoembryonic antigen immunotoxin: a therapeutic immunoconjugate for human colon cancer. Cancer Res. 1991 Jan 1;51(1):255–260. [PubMed] [Google Scholar]
  24. Jin F. S., Youle R. J., Johnson V. G., Shiloach J., Fass R., Longo D. L., Bridges S. H. Suppression of the immune response to immunotoxins with anti-CD4 monoclonal antibodies. J Immunol. 1991 Mar 15;146(6):1806–1811. [PubMed] [Google Scholar]
  25. Johnson V. G., Wilson D., Greenfield L., Youle R. J. The role of the diphtheria toxin receptor in cytosol translocation. J Biol Chem. 1988 Jan 25;263(3):1295–1300. [PubMed] [Google Scholar]
  26. Johnson V. G., Wrobel C., Wilson D., Zovickian J., Greenfield L., Oldfield E. H., Youle R. Improved tumor-specific immunotoxins in the treatment of CNS and leptomeningeal neoplasia. J Neurosurg. 1989 Feb;70(2):240–248. doi: 10.3171/jns.1989.70.2.0240. [DOI] [PubMed] [Google Scholar]
  27. Lambert J. M., McIntyre G., Gauthier M. N., Zullo D., Rao V., Steeves R. M., Goldmacher V. S., Blättler W. A. The galactose-binding sites of the cytotoxic lectin ricin can be chemically blocked in high yield with reactive ligands prepared by chemical modification of glycopeptides containing triantennary N-linked oligosaccharides. Biochemistry. 1991 Apr 2;30(13):3234–3247. doi: 10.1021/bi00227a011. [DOI] [PubMed] [Google Scholar]
  28. Manske J. M., Buchsbaum D. J., Hanna D. E., Vallera D. A. Cytotoxic effects of anti-CD5 radioimmunotoxins on human tumors in vitro and in a nude mouse model. Cancer Res. 1988 Dec 15;48(24 Pt 1):7107–7114. [PubMed] [Google Scholar]
  29. May R. D., Finkelman F. D., Wheeler H. T., Uhr J. W., Vitetta E. S. Evaluation of ricin A chain-containing immunotoxins directed against different epitopes on the delta-chain of cell surface-associated IgD on murine B cells. J Immunol. 1990 May 1;144(9):3637–3642. [PubMed] [Google Scholar]
  30. Mischak R. P., Foxall C., Rosendorf L. L., Knebel K., Scannon P. J., Spitler L. E. Human antibody responses to components of the monoclonal antimelanoma antibody ricin A chain immunotoxin XomaZyme-MEL. Mol Biother. 1990 Jun;2(2):104–109. [PubMed] [Google Scholar]
  31. O'Hare M., Brown A. N., Hussain K., Gebhardt A., Watson G., Roberts L. M., Vitetta E. S., Thorpe P. E., Lord J. M. Cytotoxicity of a recombinant ricin-A-chain fusion protein containing a proteolytically-cleavable spacer sequence. FEBS Lett. 1990 Oct 29;273(1-2):200–204. doi: 10.1016/0014-5793(90)81084-2. [DOI] [PubMed] [Google Scholar]
  32. Ogata M., Chaudhary V. K., Pastan I., FitzGerald D. J. Processing of Pseudomonas exotoxin by a cellular protease results in the generation of a 37,000-Da toxin fragment that is translocated to the cytosol. J Biol Chem. 1990 Nov 25;265(33):20678–20685. [PubMed] [Google Scholar]
  33. Oratz R., Speyer J. L., Wernz J. C., Hochster H., Meyers M., Mischak R., Spitler L. E. Antimelanoma monoclonal antibody-ricin A chain immunoconjugate (XMMME-001-RTA) plus cyclophosphamide in the treatment of metastatic malignant melanoma: results of a phase II trial. J Biol Response Mod. 1990 Aug;9(4):345–354. [PubMed] [Google Scholar]
  34. Orlandi R., Canevari S., Conde F. P., Leoni F., Mezzanzanica D., Ripamonti M., Colnaghi M. I. Immunoconjugate generation between the ribosome inactivating protein restrictocin and an anti-human breast carcinoma MAB. Cancer Immunol Immunother. 1988;26(2):114–120. doi: 10.1007/BF00205603. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Pearson J. W., FitzGerald D. J., Willingham M. C., Wiltrout R. H., Pastan I., Longo D. L. Chemoimmunotoxin therapy against a human colon tumor (HT-29) xenografted into nude mice. Cancer Res. 1989 Jul 1;49(13):3562–3567. [PubMed] [Google Scholar]
  36. Pearson J. W., Hedrick E., Fogler W. E., Bull R. L., Ferris D. K., Riggs C. W., Wiltrout R. H., Sivam G., Morgan A. C., Groves E. Enhanced therapeutic efficacy against an ovarian tumor xenograft of immunotoxins used in conjunction with recombinant alpha-interferon. Cancer Res. 1990 Oct 1;50(19):6379–6388. [PubMed] [Google Scholar]
  37. Pearson J. W., Sivam G., Manger R., Wiltrout R. H., Morgan A. C., Jr, Longo D. L. Enhanced therapeutic efficacy of an immunotoxin in combination with chemotherapy against an intraperitoneal human tumor xenograft in athymic mice. Cancer Res. 1989 Sep 15;49(18):4990–4995. [PubMed] [Google Scholar]
  38. Press O. W., Martin P. J., Thorpe P. E., Vitetta E. S. Ricin A-chain containing immunotoxins directed against different epitopes on the CD2 molecule differ in their ability to kill normal and malignant T cells. J Immunol. 1988 Dec 15;141(12):4410–4417. [PubMed] [Google Scholar]
  39. Rostaing-Capaillon O., Casellas P. Parameters affecting tumor-specific delivery of anti-CD5 antibody-ricin A chain immunotoxins in vivo. Cancer Res. 1990 May 15;50(10):2909–2916. [PubMed] [Google Scholar]
  40. Spitler L. E., Mischak R., Scannon P. Therapy of metastatic malignant melanoma using Xomazyme Mel, a murine monoclonal anti-melanoma ricin A chain immunotoxin. Int J Rad Appl Instrum B. 1989;16(6):625–627. doi: 10.1016/0883-2897(89)90085-8. [DOI] [PubMed] [Google Scholar]
  41. Stoudemire J. B., Mischak R., Foxall C., Harkonen W. S., Del Rio M., Spitler L. E. The effects of cyclophosphamide on the toxicity and immunogenicity of ricin A chain immunotoxin in rats. Mol Biother. 1990 Sep;2(3):179–184. [PubMed] [Google Scholar]
  42. Sung C., Youle R. J., Dedrick R. L. Pharmacokinetic analysis of immunotoxin uptake in solid tumors: role of plasma kinetics, capillary permeability, and binding. Cancer Res. 1990 Nov 15;50(22):7382–7392. [PubMed] [Google Scholar]
  43. Thorpe P. E., Wallace P. M., Knowles P. P., Relf M. G., Brown A. N., Watson G. J., Blakey D. C., Newell D. R. Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages. Cancer Res. 1988 Nov 15;48(22):6396–6403. [PubMed] [Google Scholar]
  44. Till M., May R. D., Uhr J. W., Thorpe P. E., Vitetta E. S. An assay that predicts the ability of monoclonal antibodies to form potent ricin A chain-containing immunotoxins. Cancer Res. 1988 Mar 1;48(5):1119–1123. [PubMed] [Google Scholar]
  45. Vitetta E. S., Fulton R. J., May R. D., Till M., Uhr J. W. Redesigning nature's poisons to create anti-tumor reagents. Science. 1987 Nov 20;238(4830):1098–1104. doi: 10.1126/science.3317828. [DOI] [PubMed] [Google Scholar]
  46. Vitetta E. S., Yen N. Expression and functional properties of genetically engineered ricin B chain lacking galactose-binding activity. Biochim Biophys Acta. 1990 Jun 21;1049(2):151–157. doi: 10.1016/0167-4781(90)90035-z. [DOI] [PubMed] [Google Scholar]
  47. Wawrzynczak E. J., Cumber A. J., Henry R. V., May J., Newell D. R., Parnell G. D., Worrell N. R., Forrester J. A. Pharmacokinetics in the rat of a panel of immunotoxins made with abrin A chain, ricin A chain, gelonin, and momordin. Cancer Res. 1990 Dec 1;50(23):7519–7526. [PubMed] [Google Scholar]
  48. Wawrzynczak E. J., Cumber A. J., Henry R. V., Parnell G. D. Comparative biochemical, cytotoxic and pharmacokinetic properties of immunotoxins made with native ricin A chain, ricin A1 chain and recombinant ricin A chain. Int J Cancer. 1991 Jan 2;47(1):130–135. doi: 10.1002/ijc.2910470123. [DOI] [PubMed] [Google Scholar]
  49. Wawrzynczak E. J., Davies A. J. Strategies in antibody therapy of cancer. Clin Exp Immunol. 1990 Nov;82(2):189–193. doi: 10.1111/j.1365-2249.1990.tb05425.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Wawrzynczak E. J., Drake A. F., Watson G. J., Thorpe P. E., Vitetta E. S. Ricin B chain-containing immunotoxins prepared with heat-denatured B chain lacking galactose-binding ability potentiate the cytotoxicity of a cell-reactive ricin A chain immunotoxin. Biochim Biophys Acta. 1988 Aug 19;971(1):55–62. doi: 10.1016/0167-4889(88)90161-9. [DOI] [PubMed] [Google Scholar]
  51. Wawrzynczak E. J., Henry R. V., Cumber A. J., Parnell G. D., Derbyshire E. J., Ulbrich N. Biochemical, cytotoxic and pharmacokinetic properties of an immunotoxin composed of a mouse monoclonal antibody Fib75 and the ribosome-inactivating protein alpha-sarcin from Aspergillus giganteus. Eur J Biochem. 1991 Feb 26;196(1):203–209. doi: 10.1111/j.1432-1033.1991.tb15805.x. [DOI] [PubMed] [Google Scholar]
  52. Wawrzynczak E. J., Watson G. J., Cumber A. J., Henry R. V., Parnell G. D., Rieber E. P., Thorpe P. E. Blocked and non-blocked ricin immunotoxins against the CD4 antigen exhibit higher cytotoxic potency than a ricin A chain immunotoxin potentiated with ricin B chain or with a ricin B chain immunotoxin. Cancer Immunol Immunother. 1991;32(5):289–295. doi: 10.1007/BF01789046. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Weiner L. M., O'Dwyer J., Kitson J., Comis R. L., Frankel A. E., Bauer R. J., Konrad M. S., Groves E. S. Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant ricin A chain immunoconjugate. Cancer Res. 1989 Jul 15;49(14):4062–4067. [PubMed] [Google Scholar]
  54. Wrobel C. J., Wright D. C., Dedrick R. L., Youle R. J. Diphtheria toxin effects on brain-tumor xenografts. Implications for protein-based brain-tumor chemotherapy. J Neurosurg. 1990 Jun;72(6):946–950. doi: 10.3171/jns.1990.72.6.0946. [DOI] [PubMed] [Google Scholar]
  55. Yokota S., Hara H., Luo Y., Seon B. K. Synergistic potentiation of in vivo antitumor activity of anti-human T-leukemia immunotoxins by recombinant alpha-interferon and daunorubicin. Cancer Res. 1990 Jan 1;50(1):32–37. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES